Aclaris Therapeutics (ACRS) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| LifeSci Capital | Initiated Coverage | Outperform | $13.00 | Jun 2, 2026 |
| Guggenheim | Initiated Coverage | Buy | $12.00 | May 5, 2026 |
| Piper Sandler | Maintained | Overweight | $11.00 from $7.00 | May 5, 2026 |
| Wedbush | Maintained | Outperform | $10.00 from $8.00 | Apr 29, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $10.00 | Apr 16, 2026 |
| Wedbush | Maintained | Outperform | $8.00 | Mar 31, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $16.00 | Mar 19, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $16.00 | Jan 28, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $16.00 | Jan 21, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $16.00 | Oct 20, 2025 |
| Piper Sandler | Initiated Coverage | Overweight | $6.00 | Jul 10, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $16.00 | Jun 25, 2025 |
| Wedbush | Initiated Coverage | Outperform | $8.00 | May 28, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $16.00 from $20.00 | May 14, 2025 |
| Scotiabank | Maintained | Sector Outperform | $9.00 from $15.00 | May 9, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | — | Mar 18, 2025 |
| Scotiabank | Initiated Coverage | Sector Outperform | $15.00 | Mar 7, 2025 |
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $20.00 | Dec 23, 2024 |
| BTIG | Upgraded | Neutral → Buy | $8.00 | Nov 19, 2024 |
| Jefferies | Upgraded | Hold → Buy | $7.00 from $2.00 | Nov 19, 2024 |
Frequently asked questions
Is ACRS a buy, sell, or hold?
Analysts covering Aclaris Therapeutics currently average a Buy rating: 11 buy, 1 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on ACRS?
On Jun 2, 2026, LifeSci Capital initiated coverage of Aclaris Therapeutics at Outperform with a price target of $13.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.